Industry News
Avexa still in the HIV game
Avexa is still working on developing next generation treatments for HIV following a turbulent couple of years, including the dumping of board in 2010 which ceased development of its lead HIV drug apcicitabine (ATC). [ + ]
Immuron C. difficile study shows 100% survival
Immuron (ASX:IMC) has reported a 100% survival rate from animal trials of the C. difficile treatment candidate it is developing with Monash University. [ + ]
Biota, Nabi amend merger terms to placate shareholder
Biota Holdings (ASX:BTA) and US-based Nabi Pharmaceuticals have amended the terms of their proposed merger, in a bid to placate Nabi shareholders seeking to block the deal. [ + ]
Nexvet raises $2.5m to fund human-to-animal drugs
Nexvet Biopharma has closed a $2.5 million seed financing round, after receiving an investment from the universities-led Trans Tasman Commercialisation Fund (TTCF). [ + ]
New joint initiative to promote biotech and GM in agriculture
A new industry group, the Agricultural Biotechnology Council of Australia (ABCA) has been formed to promote and encourage debate on the use of biotechnology and gene technology in agriculture in Australia. [ + ]
Nominations called for Janssen 2012 Industry Excellence Awards
Janssen & AusBiotech are pleased to announce that the Janssen 2012 Industry Excellence Awards, in three categories, are now open for nominations. [ + ]
Genetic test predicts risk for autism
A team of Australian researchers, led by the University of Melbourne, has developed a genetic test that is able to predict the risk of developing Autism Spectrum Disorder (ASD). [ + ]
ANU sells time machine
A SHRIMP IIe advanced geochronology instrument manufactured by ANU spin-off Australian Scientific Instruments has been purchased by Polish and Japanese researchers to investigate the geochronology of the Earth. [ + ]
Burnet discovery paves the way for more effective vaccines
Scientists have discovered an important mechanism in which a synthetic DNA targets the immune system that could significantly improve the effectiveness of future vaccines. [ + ]
Bionomics acquires American cancer stem cell company
Bionomics (ASX:BNO) has acquired US-based cancer stem cell drug development company Eclipse Therapeutics in a deal worth US$10 million ($9.5 million). [ + ]
Prosthetic device restores and improves decision-making ability in animals
An electronic prosthetic system has been used on monkeys to restore and improve the animals’ decision-making performances. [ + ]
Priceline to stock Cellmid hair growth range
Cellmid (ASX:CDY) subsidiary Advangen has now secured agreements with over 700 pharmacies including Priceline stores to stock its evolis line of hair growth products. [ + ]
AusBiotech makes submission on R&D Tax Incentive quarterly payments
AusBiotech has been advocating for quarterly payments since its first submission on the Tax Credit and is pleased to see the Government responsive to the cash-flow needs of small companies, giving companies the ability to smooth out cash-flow over the year and provide increased predictability. [ + ]
Phylogica looks to recoup $1.9m from R&D Tax Incentive
The first wave of companies is beginning to take advantage of the government’s recently installed R&D Tax Incentive, with Phylogica (ASX:PYC) lodging an application to recoup $1.9 million in research and development costs. [ + ]
Bioniche FY12 loss doubles to $24m
Bioniche (ASX:BNC) said its net loss for FY12 nearly doubled to C$24.1 million ($23.6 million), even as revenue from its animal health division grew by over 10%. [ + ]
